Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>Debt-equity exchange agreement. Vivos has signed a binding agreement with senior secured lender Streeterville Capital to exchange up to $4.5MM of outstanding debt into a mix of perpetual nonconvertible preferred stock and common stock, paired with Streeterville commitments to suspend repayment calls for 90 days and sales of company securities for 60 days from the agreement’s effective date.</li><li>The deal follows Vivos’ submission of a plan to regain Nasdaq compliance after an April 17, 2026, deficiency letter flagging that its stockholders’ equity fell short of the $2.5MM continued-listing minimum.</li><li>Year-end 2025 equity was negative $1.5MM, and despite raising $5.6MM in 1Q26, it remained at negative $1.1MM by quarter-end. </li></ul>

Debt-equity exchange agreement. Vivos has signed a binding agreement with senior secured lender Streeterville Capital to exchange up to $4.5MM of outstanding debt into a mix of perpetual nonconvertible preferred stock and common stock, paired with Streeterville commitments to suspend repayment calls for 90 days and sales of company securities for 60 days from the agreement’s effective date.The deal follows Vivos’ submission of a plan to regain Nasdaq compliance after an April 17, 2026, deficiency letter flagging that its stockholders’ equity fell short of the $2.5MM continued-listing minimum.Year-end 2025 equity was negative $1.5MM, and despite raising $5.6MM in 1Q26, it remained at negative $1.1MM by quarter-end. 

VVOS: Planned Debt-Equity Exchange Cuts Leverage and Advances Toward Nasdaq Remediation

Vivos Therapeutics

VVOS: Planned Debt-Equity Exchange Cuts Leverage and Advances Toward Nasdaq Remediation